Browse DLL3

Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type I membrane protein
Domain PF00008 EGF-like domain
PF12661 Human growth factor-like EGF
Function

Inhibits primary neurogenesis. May be required to divert neurons along a specific differentiation pathway. Plays a role in the formation of somite boundaries during segmentation of the paraxial mesoderm (By similarity).

> Gene Ontology
 
Biological Process GO:0001501 skeletal system development
GO:0001756 somitogenesis
GO:0003002 regionalization
GO:0007219 Notch signaling pathway
GO:0007386 compartment pattern specification
GO:0007389 pattern specification process
GO:0007498 mesoderm development
GO:0009952 anterior/posterior pattern specification
GO:0010721 negative regulation of cell development
GO:0035282 segmentation
GO:0048339 paraxial mesoderm development
GO:0050768 negative regulation of neurogenesis
GO:0051961 negative regulation of nervous system development
GO:0060485 mesenchyme development
GO:0061053 somite development
Molecular Function GO:0005112 Notch binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04330 Notch signaling pathway
Reactome -
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DLL3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DLL3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DLL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.890.215
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.230.354
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6740.638
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.9290.419
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6290.686
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3310.46
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0750.929
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.4730.247
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11121.9250.136
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0060.988
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.1630.793
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.9370.00272
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DLL3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.117.6-10.50.607
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1031033.3-23.30.423
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 414014.3-14.31
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.76.8-3.11
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 014014.3-14.31
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DLL3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DLL3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DLL3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DLL3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DLL3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DLL3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDLL3
Namedelta-like 3 (Drosophila)
Aliases SCDO1; delta (Drosophila)-like 3; delta3; drosophila Delta homolog 3; Delta-like protein 3
Chromosomal Location19q13.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DLL3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.